UOC
UBS O'Connor Portfolio holdings
AUM
$1.93B
1-Year Return
38.75%
This Quarter Return
+5.87%
1 Year Return
+38.75%
3 Year Return
+182.42%
5 Year Return
+480.25%
10 Year Return
+1,573.29%
AUM
$4.01B
AUM Growth
+$484M
(+14%)
Cap. Flow
+$336M
Cap. Flow
% of AUM
8.39%
Top 10 Holdings %
Top 10 Hldgs %
56.46%
Holding
586
New
87
Increased
121
Reduced
176
Closed
112
Top Buys
| 1 |
Kellanova
K
|
$305M |
| 2 |
SRCL
Stericycle Inc
SRCL
|
$145M |
| 3 |
MRO
Marathon Oil Corporation
MRO
|
$104M |
| 4 |
CHX
ChampionX
CHX
|
$98.2M |
| 5 |
Spirit AeroSystems
SPR
|
$90.4M |
Top Sells
| 1 |
ETRN
Equitrans Midstream Corporation Common Stock
ETRN
|
$149M |
| 2 |
CERE
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
|
$81.8M |
| 3 |
SWN
Southwestern Energy Company
SWN
|
$56.7M |
| 4 |
Union Pacific
UNP
|
$24.2M |
| 5 |
X
US Steel
X
|
$18.7M |
Sector Composition
| 1 | Energy | 21.14% |
| 2 | Technology | 19.82% |
| 3 | Healthcare | 14.53% |
| 4 | Industrials | 11.25% |
| 5 | Consumer Staples | 9.11% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
276
KALA BIO
KALA
$102M
| $927K | 0.02% |
162,663
+15,109
| +10% | +$86.1K |
|
277
Cooper Companies
COO
$13.5B
| $914K | 0.02% |
8,286
+2,997
| +57% | +$331K |
|
|
SWTX
278
DELISTED
SpringWorks Therapeutics
SWTX
| $914K | 0.02% |
28,513
-3,701
| -11% | -$119K |
|
279
Alphatec Holdings
ATEC
$2.43B
| $902K | 0.02% |
162,297
+58,526
| +56% | +$325K |
|
280
TG Therapeutics
TGTX
$5.11B
| $899K | 0.02% |
+38,417
| New | +$899K |
|
281
Denali Therapeutics
DNLI
$2.26B
| $896K | 0.02% |
30,744
-773
| -2% | -$22.5K |
|
282
Arcutis Biotherapeutics
ARQT
$2.06B
| $856K | 0.02% |
+92,019
| New | +$856K |
|
283
Adaptive Biotechnologies
ADPT
$1.96B
| $846K | 0.02% |
165,274
+99,529
| +151% | +$510K |
|
|
BCYC
284
Bicycle Therapeutics
BCYC
$483M
| $814K | 0.02% |
35,976
-51,084
| -59% | -$1.16M |
|
|
SLRN
285
DELISTED
ACELYRIN
SLRN
| $807K | 0.02% |
163,724
+82,312
| +101% | +$406K |
|
286
MoonLake Immunotherapeutics
MLTX
$3.77B
| $807K | 0.02% |
+16,000
| New | +$807K |
|
287
Relay Therapeutics
RLAY
$710M
| $793K | 0.02% |
+112,048
| New | +$793K |
|
288
Structure Therapeutics
GPCR
$1.27B
| $790K | 0.02% |
+18,000
| New | +$790K |
|
289
Soleno Therapeutics
SLNO
$3.71B
| $784K | 0.02% |
15,536
+536
| +4% | +$27.1K |
|
|
SYRS
290
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
| $773K | 0.02% |
359,305
+81,202
| +29% | +$175K |
|
291
Cullinan Oncology
CGEM
$413M
| $770K | 0.02% |
45,975
-16,000
| -26% | -$268K |
|
292
D.R. Horton
DHI
$54.2B
| $759K | 0.02% |
3,978
-40,275
| -91% | -$7.68M |
|
293
Bausch + Lomb
BLCO
$5.31B
| $752K | 0.02% |
+39,000
| New | +$752K |
|
294
Ovid Therapeutics
OVID
$87.5M
| $741K | 0.02% |
628,290
+340,000
| +118% | +$401K |
|
295
ON Semiconductor
ON
$20.1B
| $726K | 0.02% |
10,000
-5,000
| -33% | -$363K |
|
|
CNTB
296
Connect Biopharma Holdings Limited Ordinary Shares
CNTB
$97.5M
| $725K | 0.02% |
510,701
| – | – |
|
297
Disc Medicine
IRON
$2.11B
| $722K | 0.02% |
14,683
+1,364
| +10% | +$67K |
|
298
Marvell Technology
MRVL
$54.6B
| $721K | 0.02% |
10,000
-90,000
| -90% | -$6.49M |
|
299
Viking Therapeutics
VKTX
$3.03B
| $716K | 0.02% |
+11,316
| New | +$716K |
|
|
THRD
300
DELISTED
Third Harmonic Bio
THRD
| $709K | 0.02% |
52,294
+3,043
| +6% | +$41.2K |
|